Citation Impact
26 standout
Citing Papers
Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers
2024 Standout
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives
2024 Standout
Works of Iris de Heer being referenced
Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).
2018
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial
2018
Author Peers
| Author | Genetics | Developmental Neuroscience | PRM | APM | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Iris de Heer | 102 | 52 | 44 | 48 | 20 | 222 | |
| Emily Hembacher | 2 | 1 | 2 | 20 | 860 | ||
| Diane Oenning Thompson | 2 | 4 | 17 | 13 | 24 | 1.2k | |
| Martha Jacob | 5 | 6 | 358 | ||||
| Olav Eldholm | 1 | 91 | 7.1k | ||||
| M. Nagini | 29 | 414 |
All Works
Login with ORCID to disown or claim papers
Loading papers...